Rigel Pharmaceuticals | RIGL - Operating Expenses


Rigel Pharmaceuticals reported $117.61M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Agenus USD 19.81M 293.94M Dec/2025
Amgen USD 4.78B 1.12B Mar/2026
Anika Therapeutics USD 133.9M 103.93M Mar/2026
Arrowhead Research USD 223.22M 10.86M Dec/2025
AstraZeneca USD 8.18B 4.35B Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Celldex Therapeutics USD 87.27M 511.09M Dec/2025
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Intrexon USD 61.56M 26.1M Jun/2024
Ionis Pharmaceuticals USD 364M 54M Mar/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Ligand Pharmaceuticals USD 8.29M 32.17M Sep/2025
MacroGenics USD 53.32M 13.68M Dec/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Pfizer USD 90.1B 77.19B Mar/2026
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Veracyte USD 116M 7.24M Dec/2025